Business Context and Reporting Period
This Form 8-K is a current report filed by TrovaGene, Inc. (not Cardiff Oncology, Inc.) on February 15, 2012, covering events occurring on February 10 and February 14, 2012. The company is a Delaware corporation headquartered in San Diego, California.
Key Financial Metrics
The filing details a private placement transaction rather than standard periodic financial results. Key metrics from the transaction include:
- Gross Proceeds: $950,000
- Securities Sold: 1,900,000 Units
- Price per Unit: $0.50
- Unit Composition: One share of common stock and one warrant to purchase one share of common stock.
- Transaction Costs: $60,500 in cash and 74,700 units issued to selling agents.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity outside of this specific transaction.
Material Changes
The primary material change is the unregistered sale of equity securities. The company raised $950,000 through the issuance of 1,900,000 units. This transaction increases the company's cash position by the net proceeds after deducting the $60,500 cash fee and the value of the 74,700 units issued to agents.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard reliance on Section 4(2) of the Securities Act of 1933 for the exemption from registration. The warrants issued in the offering expire on December 31, 2018, and are exercisable at $0.50 per share.
Investor Verification Checklist
- Verify the exact net cash proceeds after accounting for the 74,700 units issued to selling agents.
- Confirm the total number of shares outstanding post-transaction to assess dilution.
- Review the full text of the Warrant agreement (Exhibit 4.1) for specific terms and conditions.
- Check subsequent filings for the use of proceeds and any additional capital raises.